508 related articles for article (PubMed ID: 25073663)
1. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
[TBL] [Abstract][Full Text] [Related]
2. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
[TBL] [Abstract][Full Text] [Related]
3. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
Hoy SM
CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
6. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
Wray S; Hayward B; Dangond F; Singer B
Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
[TBL] [Abstract][Full Text] [Related]
7. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Hu X; Shang S; Nestorov I; Hasan J; Seddighzadeh A; Dawson K; Sperling B; Werneburg B
Br J Clin Pharmacol; 2016 Aug; 82(2):380-8. PubMed ID: 27060836
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
[TBL] [Abstract][Full Text] [Related]
11. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
12. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
[TBL] [Abstract][Full Text] [Related]
13. [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].
Leussink VI; Warnke C; Tackenberg B; Wiendl H; Kieseier BC
Nervenarzt; 2015 Apr; 86(4):483-90. PubMed ID: 25833401
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
Ghezzi A; Bianchi A; Baroncini D; Bertolotto A; Malucchi S; Bresciamorra V; Lanzillo R; Milani N; Martinelli V; Patti F; Chisari C; Rottoli M; Simone M; Paolicelli D; Visconti A;
Neurol Sci; 2017 Nov; 38(11):1999-2005. PubMed ID: 28831635
[TBL] [Abstract][Full Text] [Related]
18. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
20. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
